Email updates

Keep up to date with the latest news and content from BMC Biochemistry and BioMed Central.

This article is part of the supplement: Ubiquitin-Proteasome System in Disease Part 2

Open Access Highly Accessed Review

HPV E6, E6AP and cervical cancer

Sylvie Beaudenon1 and Jon M Huibregtse2*

Author Affiliations

1 Asuragen, Inc., 2150 Woodward, Austin, TX 78744, USA

2 Molecular Genetics and Microbiology, Institute for Cellular and Molecular Biology, University of Texas at Austin, Austin, TX 78712, USA

For all author emails, please log on.

BMC Biochemistry 2008, 9(Suppl 1):S4  doi:10.1186/1471-2091-9-S1-S4

Published: 21 October 2008


Every year, approximately 470,000 new cases of cervical cancer are diagnosed and approximately 230,000 women worldwide die of the disease, with the majority (~80%) of these cases and deaths occurring in developing countries. Human papillomaviruses (HPVs) are the etiological agents in nearly all cases (99.7%) of cervical cancer, and the HPV E6 protein is one of two viral oncoproteins that is expressed in virtually all HPV-positive cancers. E6 hijacks a cellular ubiquitin ligase, E6AP, resulting in the ubiquitylation and degradation of the p53 tumor suppressor, as well as several other cellular proteins. While the recent introduction of prophylactic vaccines against specific HPV types offers great promise for prevention of cervical cancer, there remains a need for therapeutics. Biochemical characterization of E6 and E6AP has suggested approaches for interfering with the activities of these proteins that could be useful for this purpose.

Publication history

Republished from Current BioData's Targeted Proteins database (TPdb; webcite).